Consequently, inhibition of class IA PI3Ks – p110α, p110β and p110δ – represents an important strategy for the development of novel cancer therapeutics, and, moving forward, is anticipated to have a significant impact on the discovery and development of new personalized medicines in the oncology setting. The gene discussed is PIK3CD; the disease is cancer.